Predicting metastasis with novel prognostic liquid biopsy for uveal melanoma

Article

Investigators from the Karolinska Institutet and St. Erik Eye Hospital, Stockholm, Sweden, reported that they have developed a prognostic test, referred to as serUM, that they believe is a strong predictor of metastasis of uveal melanoma.

Predicting metastasis with novel prognostic liquid biopsy for uveal melanoma

Dr Christina Herrspiegel and colleagues from the Karolinska Institutet and St. Erik Eye Hospital, Stockholm, Sweden, reported that they have developed a prognostic test, referred to as serUM, that they believe is a strong predictor of metastasis of uveal melanoma.

The test is based on serum obtained from peripheral blood samples at the time of diagnosis of uveal melanoma in 83 patients (52% women; mean age at diagnosed, 65 years) from 1996 to 2000 at St. Erik Eye Hospital, they explained. All patients were diagnosed with primary melanoma in the choroid or ciliary body.

The investigators performed both proteome profiling of 84 different cancer-related proteins to screen for potential biomarkers and an enzyme-linked immunosorbent assay to evaluate the serum levels of the best protein candidates. Receiver operating characteristics were used to define thresholds for metastatic risk, they explained.

The prognostic test, serUM, was developed in a training cohort and tested in a validation cohort.

In the study patients, the mean tumour diameter and thickness were, respectively, 9.8 mm and 4.9 mm.

The proteome profiling evaluated 5 proteins, Leptin, Osteopontin, Progranulin, Tenascin C, and DLL-1, for further analysis. The prognostic test was based on the Leptin and Osteopontin concentrations developed in the training cohort (n = 17) and then tested in a validation cohort (n = 62) after exclusion of three patients with unreliable total protein fractions, the authors reported.

The results showed that with each increasing metastatic risk category, the patients had gradually shorter cumulative metastasis-free survival (log rank p for trend = 0.01).

Multivariate Cox regression analysis indicated that serUM was an independent predictor of metastasis when entering all of the following as covariates, the tumor diameter, tumour thickness, and patient age at diagnosis (hazard ratio 2.4, 95% confidence interval, 1.0-5.3).

Dr Herrspiegel and coauthors concluded, “serUM, a prognostic test based on serum obtained from a peripheral blood sample at diagnosis of uveal melanoma, is a strong predictor of metastasis.” They emphasized the need for future prospective studies to validate the findings of the current study.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.